Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Aislinn Antrim serves as Managing Editor at Pharmacy Times.

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Sarfaraz K. Niazi, PhD, discusses the regulatory approval of future messenger RNA (mRNA) vaccines, which will likely face fewer patent issues and are easy to replicate.